PT-141 (Bremelanotide): The Melanocortin Peptide That Went the Whole Way Through Approval
Most research peptides never reach a regulator. Bremelanotide did — it is an FDA-approved drug. Here is the mechanism, what separates it from every other compound in this category, and the distinction that matters when you buy research-grade material.
- PT-141 (bremelanotide) is a synthetic melanocortin-receptor agonist, structurally derived from the alpha-MSH analogue Melanotan II.
- Unlike almost every other peptide in a research catalogue, bremelanotide completed clinical development: the FDA approved it as Vyleesi in June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women.
- It acts centrally on melanocortin receptors in the nervous system rather than on the vascular pathway targeted by PDE5 inhibitors — a genuinely different mechanism, not a variation on one.
- The approved pharmaceutical and research-grade material are not the same thing; research-grade is a laboratory reagent with no prescription, pharmacist or clinical oversight attached.
- Popular Peptides supplies PT-141 at greater than 99% purity, HPLC and LC-MS verified, with a batch-specific certificate of analysis.
- For in vitro laboratory research use only — not approved by Health Canada for therapeutic use and not for human or veterinary consumption.
A research peptide with an unusual pedigree
Open any peptide catalogue and nearly everything in it shares a status: interesting mechanism, some preclinical data, maybe a Phase 2, never approved. PT-141 is the exception.
Bremelanotide — the compound sold here as PT-141 — went the entire distance. It was approved by the FDA in June 2019 under the brand name Vyleesi, for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Very few compounds that circulate in research supply chains can say that.
That pedigree matters for a laboratory buyer, because it means the pharmacology is unusually well characterised. You are not working with a molecule whose receptor behaviour is inferred from three papers.
The mechanism, and why it is genuinely different
PT-141 descends from Melanotan II, an alpha-MSH analogue originally developed as a tanning agent. Researchers noticed effects that had nothing to do with pigmentation, traced them to melanocortin receptor activity in the central nervous system, and developed a derivative that kept the neurological activity.
The result acts on **melanocortin receptors in the brain**, not on peripheral vasculature. That is the important contrast. PDE5 inhibitors — sildenafil and its relatives — work downstream on blood flow. Bremelanotide works upstream on central signalling pathways. In pharmacological terms these are not competing versions of the same idea; they operate on entirely separate systems.
For a research setting, that makes PT-141 a useful tool for probing melanocortin receptor signalling specifically, in a way that vascular agents cannot.
Related compounds in this catalogue worth reading alongside it: kisspeptin, which sits further upstream on the reproductive axis, and oxytocin, studied in social and bonding pathways. Full molecular data for each is in our reference library.
The distinction you need to be clear about
Bremelanotide being approved cuts both ways, and honest suppliers say the second part.
The approved product is a prescription pharmaceutical: manufactured to pharmacopoeial standards, dispensed by a pharmacist, prescribed and monitored by a clinician, with a defined indication and a label. Research-grade PT-141 is a different category of thing entirely — a laboratory reagent, supplied for in vitro work, with no prescription, no pharmacist and no clinical oversight. It is not the approved medicine, it is not equivalent to it, and it is not a cheaper route to it.
What research-grade material is for is laboratory work: receptor-binding studies, melanocortin pathway pharmacology, comparative in vitro work. And for that, exactly one question matters — is the compound in the vial the compound on the label, at the purity claimed?
How to be sure of what you are actually buying
This is where most of the market fails, and where the decision actually gets made.
Anyone can print "99% purity" on a product page. Almost nobody publishes the document behind it. We do, per batch:
- —**HPLC for purity and LC-MS for identity**, performed by an independent third-party lab — not by us, which is the only version of that claim worth anything.
- —**Published-batch purity averaging above 99%.** Not a target: the measured average across batches we have published.
- —**Look up your lot number** and read the certificate of analysis for the exact vial you received — measured purity, methods, analysis date, result. Or browse every published lab result before you order anything.
Then there is the part that has nothing to do with chemistry and costs people orders constantly: **we ship from inside Canada.** Vancouver, BC, typically 2 to 5 business days, tracked and insured, discreet packaging, Canadian dollars, free shipping over $300 CAD. No customs clearance. No border seizure. No three-week silence wondering whether a package cleared, and no support address that answers in a different time zone next week.
Most research compounds bought in Canada come from overseas and take that risk on every single order. Ours do not cross a border.
Frequently asked questions
What is PT-141?
PT-141, also called bremelanotide, is a synthetic melanocortin-receptor agonist derived structurally from the alpha-MSH analogue Melanotan II. It acts on melanocortin receptors in the central nervous system. The material supplied here is research-grade, for in vitro laboratory use only.
Is PT-141 approved?
The pharmaceutical form was approved by the FDA in June 2019 as Vyleesi, for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Research-grade PT-141 is not that product, is not approved for therapeutic use, and is supplied for laboratory research only.
How does PT-141 differ from PDE5 inhibitors?
Mechanistically they are unrelated. PDE5 inhibitors act peripherally on vascular smooth muscle and blood flow. Bremelanotide acts centrally on melanocortin receptor signalling in the nervous system.
What purity is your PT-141?
Greater than 99%, verified by HPLC for purity and LC-MS for identity by an independent third-party laboratory. Every batch has a certificate of analysis you can retrieve by lot number on our verification page.
Where can I buy PT-141 in Canada?
Popular Peptides supplies PT-141 for laboratory research use, shipped domestically from Vancouver, BC with a third-party certificate of analysis verifiable by lot number. It is not sold for human or veterinary consumption.
PT-141 is supplied for in vitro laboratory research use only. It is not the approved pharmaceutical product, is not approved by Health Canada for therapeutic use, and is not intended for human or veterinary consumption. 18+.
Every batch we sell is independently third-party tested, with the full Certificate of Analysis published and checkable by lot number.